An FGFR1/2/3 inhibitor combined with chemotherapy or immunotherapy was evaluated in solid tumors in an open-label, Phase 1/2 study. Learn more about our findings in patients with FGFR alterations. https://bit.ly/3yt2D7V
Incyte Medical’s Post
More Relevant Posts
-
🎙 Tune in to OncologyTube.com to hear our Vice President of Clinical Development, Kellogg Parsons, MD, MHS, FACS at #SABC23, overview the applications of our lead investigational #ADC therapeutic, MBRC- 101, which targets EphA5 in advanced #solidtumors and shows promise in various cancers, including #breastcancer subtypes. Listen here: https://lnkd.in/gckw7gqW
Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors - SABCS 2023
oncologytube.com
-
Learn about NEXUS-01, our Phase 1 trial of an investigational #Nectin4 targeted antibody-drug conjugate in patients with advanced or metastatic #UrothelialCarcinoma or other solid tumors. Find detailed trial and enrollment information here: https://e.lilly/3VR2ns8 #CancerResearch #ClinicalTrials #ADCs #BladderCancer
-
-
Biotech | Medicine | Translational | Market Intelligent | Business Dev. | Help Each Other Success | Med Device | The Community Guy | Speaking for himself
Multi-omics inspection of clinical pd-1 resistant NSCLC reveals that Galectin-9 expressing tumor cells sustained the primary resistance of neoadjuvant anti-PD-1 therapy in NSCLC through galectin-9/TIM-3-mediated suppression of imcDC2 and CD8+ TRMs. https://lnkd.in/gxWT82MQ
-
De-escalation studies are critically important to providing personalised care. Important data and a step in the right direction.
A circulating tumor DNA-guided adaptive de-escalation TKI treatment strategy is feasible for patients with advanced NSCLC and undetectable ctDNA for achieving complete remission after local consolidative therapy. https://ja.ma/3Vmq7D1
-
-
Medical oncologists review updated data from the PAPILLON trial on amivantamab plus chemotherapy and discuss the treatment of patients with NSCLC with EGFR exon 20 insertions. https://lnkd.in/e92DENZZ #NSCLC #cancer #oncology
-
Neuroblastoma, MIBG scan, FDOPA and FDG PET images before/after chemotherapy. Primary tumor arising from right adrenal is avid for MIBG, FDOPA and FDG (less uptake). After chemo, MIBG and FDG are normal but FDOPA shows some residual tumor. Also see supraclavicular brown fat activity on MIBG, thymic and growth plate uptake on FDG, bilateral corpus striata and growth plate uptake on FDOPA PET. Fig from Yao Lu et al.
-
-
Please read our paper just published in JITC. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. https://lnkd.in/eXwDBGZc https://lnkd.in/ecqjqda3
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
jitc.bmj.com
-
With the advancement of two clinical trials treating KRAS G12D mutated cancers and the initiation of GLP toxicology studies for QTX3544, a G12V-preferring multi-#KRAS inhibitor, we aim to address the significant unmet need for patients with KRAS-mutated cancer beyond G12C.
Excited to share we’ve dosed our first patient in the Phase 1/1b clinical trial of QTX3046, an oral, dual (OFF/ON)-state KRASG12D-selective inhibitor and initiated patient dosing in the combination portion of the ongoing Phase 1 trial assessing QTX3034, a G12D-preferring multi-#KRAS inhibitor. Both are enrolling patients with KRASG12D-mutated advanced solid tumors. Learn more: https://bit.ly/4ciYUZ0
-
-
A circulating tumor DNA-guided adaptive de-escalation TKI treatment strategy is feasible for patients with advanced NSCLC and undetectable ctDNA for achieving complete remission after local consolidative therapy. https://ja.ma/3WOR0S4
-
-
Excited to share we’ve dosed our first patient in the Phase 1/1b clinical trial of QTX3046, an oral, dual (OFF/ON)-state KRASG12D-selective inhibitor and initiated patient dosing in the combination portion of the ongoing Phase 1 trial assessing QTX3034, a G12D-preferring multi-#KRAS inhibitor. Both are enrolling patients with KRASG12D-mutated advanced solid tumors. Learn more: https://bit.ly/4ciYUZ0
-
